Milestone Pharmaceuticals (MIST) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 10, 2025, with shareholders voting on key proposals and receiving a report on company progress.

• Shareholders can access proxy materials online or request printed copies, and voting can be done online, by phone, mail, or during the meeting.

• The record date for voting eligibility is April 15, 2025, with 53,464,273 common shares outstanding.

Voting matters and shareholder proposals

• Proposals include electing eight directors, ratifying PwC as auditor, amending the 2019 Equity Incentive Plan, a say-on-pay vote, and a vote on the frequency of future say-on-pay votes.

• The board recommends voting FOR all director nominees, FOR the auditor and plan amendment, FOR executive compensation, and ONE YEAR for say-on-pay frequency.

• Shareholder proposals and director nominations for the 2026 meeting must be submitted by early 2026, with specific deadlines for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of eight members, seven of whom are independent; the chair is independent and separate from the CEO.

• Directors are elected annually, with no classified board or poison pill, and have a 99% attendance rate for board meetings.

• The board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.

• The company maintains a robust code of business conduct and ethics, and has adopted policies prohibiting hedging, pledging, and margin purchases by insiders.

• There are no term limits for directors, but regular board and committee assessments are conducted.